__NUXT_JSONP__("/drugs/Pomalidomide", (function(a,b,c,d){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:a,conditionIndication:"Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.",inn:b,marketingAuthorisationDate:"2013-08-05 00:00:00",marketingAuthorisationHolder:"Bristol-Myers Squibb Pharma EEIG",medicineName:"Imnovid (previously Pomalidomide Celgene)",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fimnovid"}],fdaDrugLabel:[{brand:c,indication:"1 INDICATIONS AND USAGE POMALYST is a thalidomide analogue indicated, for the treatment of adult patients: in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",manufacturer:"Celgene Corporation",splSetId:"2b25ef01-5c9e-11e1-b86c-0800200c9a66"}],id:a,nciThesaurus:{casRegistry:"19171-19-8",chebiId:"",chemicalFormula:"C13H11N3O4",definition:"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.",fdaUniiCode:"D2UX06XLB5",identifier:"C72560",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C157388","C1742","C54677"],synonyms:["3-Amino-N-(2,6-dioxo-3-piperidyl)phthalimide","4-Amino-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione","4-Aminothalidomide","Actimid","CC-4047","Imnovid","POMALIDOMIDE",a,c,b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FPomalidomide",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("Pomalidomide","pomalidomide","Pomalyst","2021-10-30T13:43:55.663Z")));